🧾 What This Document Is

This is a Form 6-K, which is a report foreign companies (like Philips, which is from the Netherlands) file with the U.S. SEC to share important news with American investors. Think of it as a mandatory news bulletin.

👉 Why it matters: This filing contains a press release about changes to Philips' top leadership—the Supervisory Board (like a company's board of directors) and its CEO. For investors, who runs the company is a critical piece of information.

🏢 What The Company Does

👉 In simple terms: Royal Philips is a major global health technology company. They make everything from MRI machines and ultrasound equipment for hospitals to electric toothbrushes and air purifiers for your home. Their goal is to improve health through innovation.

• Ticker: Trades in New York (PHG) and Amsterdam (PHIA).
• Size: About €18 billion in sales in 2025 and roughly 64,800 employees.

👥 Boardroom Shuffle: The Key Changes

This filing announces several important personnel decisions that will be voted on at the upcoming shareholder meeting.

➕ A New Director: John DeFord

Philips is proposing to appoint John DeFord to its Supervisory Board.

• Who he is: An American, born in 1962, with deep experience in the medical device industry. He was the CEO of Samothrace Medical Innovations and the former Chief Technology Officer at Becton Dickinson (a huge medical tech company).
• Why he's being added: His expertise is in regulatory affairs, quality systems (especially with the U.S. FDA), and innovation. This is crucial for Philips, which has faced significant product quality and safety challenges in recent years. His background signals a continued focus on fixing these issues and getting products approved.

🔄 Three Directors Proposed for Re-appointment

The board recommends re-appointing three current members for their valuable expertise:

• Paul Stoffels (Belgian, born 1962)
• Herna Verhagen (Dutch, born 1966)
• Sanjay Poonen (American, born 1969) 👉 Why it matters: Keeping these experienced members provides stability. They have backgrounds in medical tech, digital transformation, and global business, which aligns with Philips' strategic goals.

👋 One Director Steps Down

Marc Harrison (American, born 1964) will leave the board after his second term expires in May 2026. He has served since 2018. The Chairman thanked him for his eight years of service.

🚀 CEO Re-appointment: The Top Job

This was previously announced, but it's formalized here: Roy Jakobs (Dutch/German, born 1974) is proposed to be re-appointed as President/CEO and Chairman of the Board of Management.

• The signal: The board is endorsing Jakobs' leadership. They cite "progress made since 2022" (when he took over during a crisis) and their confidence in him to drive "profitable growth" in the company's next phase.

📅 Key Dates & Vote

All these proposed appointments and re-appointments will be put to a vote at the Annual General Meeting (AGM) of Shareholders on May 8, 2026.

⚖️ Big Picture

This filing is all about governance and leadership continuity.

• 👍 Strengths (The Board Gets More Relevant): Adding John DeFord brings crucial, hands-on U.S. medical device and FDA regulatory expertise directly to the board. This is a direct response to Philips' past issues and shows they are prioritizing quality and compliance at the highest level. Re-appointing the CEO and other directors provides stability.
• ⚠️ Risks (The Execution Challenge): The board changes acknowledge past problems. The big question remains: Can this new leadership mix successfully execute the turnaround, ensure product safety, and reignite profitable growth in a competitive market?

🧠 The Analogy

Think of Philips as a major hospital undergoing a leadership check-up. They're bringing in a renowned specialist (DeFord) known for fixing tricky operational and compliance issues, while endorsing the current head surgeon (CEO Jakobs) to continue leading the overall recovery. The board is ensuring the right experts are in the room for the next critical phase of treatment.

📇 Key Contacts & People

Authorized Contact for the SEC:

• M.J. van Ginneken (Chief Legal Officer)
• Koninklijke Philips N.V., Prinses Irenestraat 59, 1077 WV Amsterdam, The Netherlands

Investor Relations:

• Tel: +31 20 59 77055
• E-mail: [email protected]

People Mentioned in the Filing:

• John DeFord (Proposed New Supervisory Board Member)
• Paul Stoffels (Proposed Re-appointment, Supervisory Board)
• Herna Verhagen (Proposed Re-appointment, Supervisory Board)
• Sanjay Poonen (Proposed Re-appointment, Supervisory Board)
• Marc Harrison (Outgoing Supervisory Board Member)
• Roy Jakobs (Proposed Re-appointment as President/CEO & Chairman)
• Feike Sijbesma (Chairman of the Supervisory Board)

🧩 Final Takeaway

Philips is reinforcing its board with a key expert in medical device regulation while endorsing its current CEO to steer the company's turnaround. This move is a direct, strategic response to past challenges, focusing on quality, compliance, and stable leadership for the future. All these changes go to a shareholder vote on May 8, 2026.